Prognostic Implications of SMARCA4, ARID1A, and Other BAF Mutations in Non-Small Cell Lung Cancer.

Cancer Med · 2025 · PMC12700723 · PMID 41387924

Europe PMC DOI

hedged sentences

0.4000

closest p · 8.0× alpha

0.4000

boldest claim

The sentences

a numerical trendp = 0.4not close (p > 0.1)

While few studies have been published regarding the impact of ARID2 mutations in NSCLC, it is worth noting that a composite analysis of five clinical cohorts treated with ICI at MSKCC ( n = 2272) showed a numerical trend towards improved PFS (8.3 vs. 4.1 months, HR = 0.79, p = 0.4; n = 349) and OS (36 vs. 11 months, HR = 0.60, p = 0.097; n = 344) when comparing mutated to wild‐type ARID2 cases, but the differences did not reach statistical significance [ 13 ].

also in 1,012 other papers

did not reach statistical significanceno p-value reported

11 months, HR = 0.60, p = 0.097; n = 344) when comparing mutated to wild‐type ARID2 cases, but the differences did not reach statistical significance [ 13 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.